Breaking News Instant updates and real-time market news.

ADBE

Adobe

$138.05

-4.58 (-3.21%)

, GE

General Electric

09:40
06/12/17
06/12
09:40
06/12/17
09:40

Unusually active option classes on open June 12th

Unusual total active option classes on open include: Adobe (ADBE), General Electric (GE), Market Vectors Semiconductor (SMH), IBM (IBM), Technology Sector SPDR (XLK), AK Steel (AKS), Apple (AAPL), Gilead (GILD), Bank of America (BAC), and Powershares QQQ (QQQ).

ADBE

Adobe

$138.05

-4.58 (-3.21%)

GE

General Electric

SMH

Market Vectors Semiconductor

IBM

IBM

XLK

Technology Select Sector SPDR

AKS

AK Steel

AAPL

Apple

$148.98

-6.01 (-3.88%)

GILD

Gilead

$64.70

0.58 (0.90%)

BAC

Bank of America

QQQ

PowerShares QQQ Trust

$139.98

-3.59 (-2.50%)

  • 13

    Jun

  • 20

    Jun

  • 22

    Jun

  • 02

    Oct

ADBE Adobe
$138.05

-4.58 (-3.21%)

06/09/17
BMOC
06/09/17
NO CHANGE
BMOC
Adobe price target raised to $160 from $140 at BMO Capital
BMO Capital analyst Keith Bachman says that he believes that Adobe "has developed a next generation digital marketing hub." He thinks that this tool gives the company a "sustainable competitive advantage" and "significantly expands its total available market." He continues to identify the stock as his top software/SaaS pick and reiterates an Outperform rating.
05/02/17
05/02/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Adobe (ADBE) initiated with an Overweight at Barclays. 2. Okta (OKTA) initiated with a Hold at Canaccord, an Overweight at JPMorgan, and a Neutral at Goldman Sachs. 3. Enbridge (ENB) initiated with an Equal Weight at Morgan Stanley. 4. C&J Energy Services (CJ) reinitiated with an Outperform at Credit Suisse and initiated with an Equal Weight at Morgan Stanley. 5. Madison Square Garden (MSG) initiated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/02/17
LEHM
05/02/17
INITIATION
Target $155
LEHM
Overweight
Adobe initiated with an Overweight at Barclays
Barclays analyst Saket Kalia started Adobe with an Overweight rating and $155 price target. Creative Cloud migration and Marketing Cloud strength should drive 20% growth over the next two years, the analyst contends.
06/12/17
PIVT
06/12/17
DOWNGRADE
Target $112
PIVT
Sell
Adobe downgraded to Sell from Hold at Pivotal Research
Pivotal Research analyst Brian Wieser downgraded Adobe to Sell citing valuation. The analyst is positive on the company's fundamentals, but notes the current share price is 20% above his price target of $112, which is raised from $109.
GE General Electric

05/12/17
05/12/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Electric (GE) downgraded to Sell from Hold at Deutsche Bank with analyst John Inch saying the stock is overvalued given "weak earnings quality" and the "wide gap between non-cash and cash earnings." 2. Electronic Arts (EA) was downgraded to Neutral from Long-Term Buy at Hilliard Lyons and to Sell from Hold at Deutsche Bank. 3. Uni-Pixel (UNXL) downgraded to Neutral from Buy at Roth Capital with analyst Brian Alger saying while he sees abundant industry demand and interest for the company's products, he sees Uni-Pixel's future as somewhat binary and dependent upon strategic partnerships being executed relatively quickly. Alger also lowered his price target on the shares to 45c from $2. 4. Akari Therapeutics (AKTX) downgraded to Market Perform from Outperform at William Blair with analyst Tim Lugo citing the company's announcement that it placed its Chief Executive Officer on administrative leave as it reviews any involvement with the Edison Report. 5. Mazor Robotics (MZOR) downgraded to Market Perform from Outperform at JMP Securities with analyst David Turkaly citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/25/17
DBAB
05/25/17
NO CHANGE
Target $24
DBAB
Sell
GE officially walked away from 2018 EPS target, says Deutsche Bank
Deutsche Bank analyst John Inch says General Electric CEO Jeff Immelt at a conference yesterday officially walked away from the company's $2.00-plus earnings per share framework for 2018 citing tougher markets. While investors had expected GE to abandon the $2.00-plus target, the company kept $2.00 per share at the high end of its 2018 framework, Inch tells investors in a research note. He believes $2.00 to be unrealistic, even as just a high point in the range. The analyst sees cash flow pressures continuing in 2018 and keeps a Sell rating on GE with a $24 price target.
05/31/17
DBAB
05/31/17
NO CHANGE
Target $24
DBAB
Sell
General Electric setting stage for dividend cut, says Deutsche Bank
Deutsche Bank analyst John Inch believes the stage is being set for General Electric to cut its common dividend. The analyst has a Sell rating on the shares with a $24 price target. Last Wednesday at a conference, GE provided a cash flow walk for the next two years that suggests it is likely to generate insufficient free cash flow to cover its common dividend this year, and barely enough next year, Inch tells investors in a research note. He believes a "reasonable dividend payout" on a future earnings reset could result in a GE dividend cut to 65c-75c. A dividend reduction could be part of an earnings "reset" lower and possibly in conjunction with eventual future leadership change, Inch writes.
06/01/17
FBCO
06/01/17
NO CHANGE
Target $34
FBCO
Outperform
General Electric has reached attractive entry point, says Credit Suisse
Credit Suisse analyst Julian Mitchell thinks the pendulum of investor sentiment regarding General Electric has swung too far in the negative direction, creating an attractive entry point into the stock. GE's organic growth seems underappreciated, argues Mitchell, who notes that its organic sales growth has topped most Electrical Equipment and Multi-Industry peers in recent years and into 2017. Meanwhile, GE's segments have shown "fairly healthy" operating leverage, added Mitchell, who has an Outperform rating and $34 price target on GE shares.
SMH Market Vectors Semiconductor

IBM IBM

06/08/17
STFL
06/08/17
NO CHANGE
STFL
IBM defended after CNBC report at Stifel
After CNBC reported that Facebook's (FB) WhatsApp had decided to stop using IBM's (IBM) cloud service and build its own solution, Stifel analyst David Grossman says that WhatsApp accounted for a tiny portion of IBM's cloud/outsourcing revenue. The analyst reiterated that bookings disclosed by IBM so far this quarter increase his confidence that its Infrastructure Services business "can stabilize in 2H17, all else being equal." He notes that the business accounts for about 30% of the company's revenue. Devitt keeps a $182 price target and Buy rating on the stock.
05/18/17
PACS
05/18/17
INITIATION
PACS
Sector Weight
IBM initiated with a Sector Weight at Pacific Crest
05/19/17
05/19/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Bernstein initiated Nvidia (NVDA) with an Outperform and a $165 price target. 2. Cantor Fitzgerald initiated Thermo Fisher (TMO) with an Overweight rating and $194 price target. 3. Pacific Crest initiated IBM (IBM) with a Sector Weight rating. 4. Conduent (CNDT) initiated with a Market Perform rating and $18 price target at Cowen. 5. JMP Securities started coverage of Spring Bank Pharmaceuticals (SBPH) with a $20 price target and an Outperform rating. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/23/17
MAXM
05/23/17
NO CHANGE
Target $41
MAXM
Buy
Nutanix pact with IBM potentially more powerful than Dell deal, says Maxim
Maxim analyst Nehal Chokshi said he views Nutanix' (NTNX) announcement of a multi-year initiative that will combine IBM's (IBM) P-series servers and Nutanix' Enterprise Cloud Platform as a "very significant mid-term positive." He believes the partnership gives IBM a powerful infrastructure software answer to VMware (VMW) and Microsoft (MSFT) and sees the relationship with the potential to be even more powerful than the Dell relationship that powered Nutanix' improving FY16 sales productivity and cash flow. Chokshi keeps a Buy rating on Nutanix but trimmed his price target to $41 from $42 to account for Dell siphoning Nutanix leads to VMware, as previously discussed.
XLK Technology Select Sector SPDR

08/22/16
JEFF
08/22/16
NO CHANGE
JEFF
Jefferies ups SMID-cap Technology to Overweight, cuts REITs to Market Weight
Jefferies Equity Strategist Steven DeSanctis said that in terms of its SMID-cap sector strategy the firm is moving to an Overweight on Technology, citing Tech's "very strong" earnings season, reasonable valuations in the group and expectations for the recent M&A trend to continue. Also, the firm is moving Real Estate to Market Weight from Overweight, citing the belief that investors are shifting their preference towards growth and away from yield.
AKS AK Steel

05/19/17
LBOW
05/19/17
INITIATION
LBOW
Neutral
AK Steel initiated with a Neutral at Longbow
04/24/17
MACQ
04/24/17
UPGRADE
Target $8.1
MACQ
Outperform
AK Steel upgraded to Outperform from Neutral at Macquarie
Macquarie analyst Aldo Mazzaferro upgraded AK Steel to Outperform with an $8.10 price target based on valuation and expected improvement in earnings as steel market demand improves. Mazzaferro increasingly believes steel demand is improving and is sustainable, raising his 2017/18/19 earnings estimates to 38c/92c/$1.42 from 22c/80c/$1.30.
04/26/17
JEFF
04/26/17
NO CHANGE
Target $9
JEFF
Buy
AK Steel selloff a buying opportunity, says Jefferies
Jefferies analyst Seth Rosenfeld recommends buying AK Steel following yesterday's post-guidance selloff. The analyst expects the company's results to improve in the second half of 2017 amid lower raw material costs. He reiterates a Buy rating on the shares with a $9 price target.
05/25/17
CLKS
05/25/17
UPGRADE
CLKS
Buy
AK Steel upgraded to Buy from Neutral at Clarksons Platou
AAPL Apple
$148.98

-6.01 (-3.88%)

06/07/17
RBCM
06/07/17
NO CHANGE
RBCM
Analog Devices weakness will be short lived, says RBC Capital
RBC Capital analyst Amit Daryanani notes that Analog Devices (ADI) "has underperformed rather notably" since its Q2 results on May 31. The analyst blames the weakness on the company's reduced revenue from Apple (AAPL). However, he thinks that investors will begin focusing more on the company's multiple tailwinds, possibly starting in the wake of its June 20 Analyst Day. Consequently, he expects the stock to rise from current levels and keeps a $92 price target and Outperform rating on the shares.
06/07/17
ARGS
06/07/17
NO CHANGE
ARGS
Apple price target raised to $175 from $160 at Argus
Argus analyst Jim Kelleher increased his price target on Apple after the company annoucned new products and product enhancements. The analyst quotes Apple bears as saying that the company is "playing catch-up" by introducing similar products to those that its rivals have already launched. However, Kelleher says that, "coming late to the party did not hurt iPhone's leadership in smartphones." He keeps a Buy rating on the shares. .
06/11/17
MZHO
06/11/17
DOWNGRADE
Target $150
MZHO
Neutral
Apple downgraded to Neutral from Buy at Mizuho
Mizuho analyst Abhey Lamba downgraded Apple to Neutral from Buy and lowered his price target for the shares to $150 from $160. The iPhone maker fell along with the Nasdaq index late in Friday's trade to close down 4%, or $6.01, to $148.98. "Enthusiasm" around the upcoming iPhone launch is fully priced in after the stock's year-to-date outperformance, Lamba wrote to investors Sunday night. The analyst sees limited upside to consensus estimates and notes Apple shares are trading near the upper-end of their recent valuation range.
06/12/17
BERN
06/12/17
NO CHANGE
BERN
Apple slowdown in China probably a temporary pause, says Bernstein
Bernstein analyst A.M. (Toni) Sacconaghi, Jr. says that weakening sales of Apple's iPhone in China is probably due to a temporary pause in demand ahead of the company's new iPhone scheduled to debut later this year, rather than a result of competition from other high-end devices. The analyst continues to believe that Apple's risk/reward ratio is attractive and keeps a $160 price target and Outperform rating on the stock.
GILD Gilead
$64.70

0.58 (0.90%)

05/30/17
LEER
05/30/17
NO CHANGE
Target $74
LEER
Market Perform
Gilead HIV combo data should reassure investors, says Leerink
Leerink analyst Geoffrey Porges said Gilead's (GILD) Phase 3 data for its HIV combination treatment featuring bictegravir should "provide significant reassurance for investors" given that the drug is an essential part of the company's HIV strategy and portfolio and was found to be equal to, though not better than, the "gold standard," namely GlaxoSmithKline's (GSK) dolutegravir combo. Porges, who attributes $12-13 per share in value from bictegravir in his current model for Gilead, notes that his peak global forecast of $10.6B for bictegravir containing combination revenue is nearly double the current consensus peak sales estimate of $5.6B. Porges keeps a Market Preform rating and $74 price target on Gilead shares.
04/25/17
JMPS
04/25/17
NO CHANGE
JMPS
Johsnson &Johnson data positive for Achillion, says JMP Securities
JMP Securities analyst Liisa Bayko says that data on a triple combination HCV treatment presented by Johnson & Johnson (JNJ) yesterday is positive for Achillion (ACHN). The analyst noted that the triple combination includes Achillion's odalasvir and that the six week treatment regimen is shorter than the eight weeks required for Gilead's (GILD) Harvoni. The analyst says that Achillion's stock dropped sharply yesterday because there was disappointment over the combination's efficacy in genotype 3 patients. However, she says that such patients only represent 10% of the total, and she says that Achillion can "conservatively" obtain peak royalty revenue of about $100M from its drug. Bayko keeps a $13 price target and an Outperform rating on the shares.
04/25/17
WELS
04/25/17
NO CHANGE
WELS
Gilead Q1 results poised to beat expectations, says Wells Fargo
After analyzing prescription data for January and February, Wells Fargo says that prescriptions of Gilead's HIV and HCV drugs were tracking ahead of expectations. The firm says the company's Q1 results appear on track to beat expectations.
05/30/17
JPMS
05/30/17
NO CHANGE
JPMS
Overweight
JPMorgan 'generally encouraged' by Gilead bictegravir data
After Gilead (GILD) announced top-line data from four Phase 3 studies of its HIV combo regimen containing bictegravir, JPMorgan analyst Cory Kasimov said he was "generally encouraged by the news, though not entirely surprised" given the previously communicated Phase 2 results. As he has previously noted, Kasimov thinks the launch of the bictegravir combo in 2018 could be key for Gilead to help maintain market share in the face of continued growth of GlaxoSmithKline's (GSK) dolutegravir combo and a wave of patent expirations. The analyst keeps an Overweight rating on Gilead shares.
BAC Bank of America

06/09/17
RBCM
06/09/17
NO CHANGE
RBCM
House financial reform bill unlikely to advance in Senate, says RBC Capital
RBC Capital analyst Gerard Cassidy says that the financial regulation reform bill passed yesterday by the House would help the banking sector but probably won;t be passed by the Senate. Large publicly traded banks include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
04/24/17
04/24/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Disney (DIS) downgraded to Hold from Buy at Loop Capital with analyst David Miller citing valuation following the stock hitting a 52-week high on Friday. The strength in the stock over the last nine months has appropriately priced in the company's growth rate, said Miller, who maintains a $118 price target on Disney shares. 2. Groupon (GRPN) downgraded to Underweight on lackluster ad spend at Morgan Stanley with analyst Brian Nowak saying its recent local advertiser survey indicate lackluster forward advertiser spending and believes Groupon will need to spend more in order to grow North America Local Billings, which the Street seems to be underestimating. 3. Grainger (GWW) downgraded to Market Perform from Outperform at William Blair with analyst Ryan Merkel citing a lack of confidence in the company's repricing strategy. 4. Bank of America (BAC) downgraded to Hold from Buy at Berenberg with analyst James Chappell saying it is time to take profits. Interest rates unlikely to rise as much as has been priced into bank equity valuations, Chappell tells investors in a research note. Further, regulation and tax reform are likely to take longer than expected and not be as beneficial for the banks as many might have hoped, the analyst adds. He upped his price target for Bank of America shares to $22 from $15. 5. DuPont Fabros (DFT) downgraded to Hold from Buy at Stifel with analyst Matthew Heinz saying shares are fully valued and demand patterns have shifted. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/24/17
BREN
04/24/17
DOWNGRADE
Target $22
BREN
Hold
Bank of America downgraded to Hold from Buy at Berenberg
Berenberg analyst James Chappell downgraded Bank of America to Hold saying it is time to take profits. Interest rates unlikely to rise as much as has been priced into bank equity valuations, Chappell tells investors in a research note. Further, regulation and tax reform are likely to take longer than expected and not be as beneficial for the banks as many might have hoped, the analyst adds. He upped his price target for Bank of America shares to $22 from $15.
04/19/17
RBCM
04/19/17
NO CHANGE
RBCM
Bank of America reported 'knockout' results, says RBC Capital
RBC Capital analyst Gerard Cassidy says that Bank of America reported "knockout" Q1 results that were better than the other three "Big Four" banks. The analyst says that the company has momentum heading into the rest of the year. He keeps a $26 price target and an Outperform rating on the shares.
QQQ PowerShares QQQ Trust
$139.98

-3.59 (-2.50%)

TODAY'S FREE FLY STORIES

ADP

ADP

$111.10

-0.48 (-0.43%)

13:21
08/17/17
08/17
13:21
08/17/17
13:21
Recommendations
ADP analyst commentary  »

ADP will have difficulty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 11

    Sep

NAK

Northern Dynasty

$1.56

0.065 (4.36%)

13:20
08/17/17
08/17
13:20
08/17/17
13:20
Options
Call buyers back in Northern Dynasty Minerals »

Call buyers back in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLS

Celestica

$11.55

-0.035 (-0.30%)

13:17
08/17/17
08/17
13:17
08/17/17
13:17
Upgrade
Celestica rating change  »

Follow-up: Celestica…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSRO

Tesaro

$112.99

-1.01 (-0.89%)

, AZN

AstraZeneca

$29.12

-0.0637 (-0.22%)

13:17
08/17/17
08/17
13:17
08/17/17
13:17
Hot Stocks
Breaking Hot Stocks news story on Tesaro, AstraZeneca »

Tesaro drops 2% after FDA…

TSRO

Tesaro

$112.99

-1.01 (-0.89%)

AZN

AstraZeneca

$29.12

-0.0637 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 08

    Sep

  • 08

    Sep

$NSD

NASDAQ Market Internals

13:17
08/17/17
08/17
13:17
08/17/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$29.11

-0.07 (-0.24%)

13:16
08/17/17
08/17
13:16
08/17/17
13:16
Hot Stocks
FDA posts approval of new dosage form for AstraZeneca's Lynparza 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Sep

  • 08

    Sep

$NYE

NYSE Market Internals

13:16
08/17/17
08/17
13:16
08/17/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$19.72

-1.17 (-5.60%)

, LVLT

Level 3

$53.45

-1.73 (-3.14%)

13:13
08/17/17
08/17
13:13
08/17/17
13:13
Hot Stocks
CenturyLink says working to finalize Level 3 deal by end of Q3 »

CenturyLink (CTL) said in…

CTL

CenturyLink

$19.72

-1.17 (-5.60%)

LVLT

Level 3

$53.45

-1.73 (-3.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$19.73

-1.16 (-5.55%)

, LVLT

Level 3

$53.45

-1.73 (-3.14%)

13:12
08/17/17
08/17
13:12
08/17/17
13:12
Hot Stocks
Breaking Hot Stocks news story on CenturyLink, Level 3 »

CenturyLink says working…

CTL

CenturyLink

$19.73

-1.16 (-5.55%)

LVLT

Level 3

$53.45

-1.73 (-3.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$111.10

-0.48 (-0.43%)

13:10
08/17/17
08/17
13:10
08/17/17
13:10
Options
ADP attracts put buyers as shares come under fire »

ADP attracts put buyers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 11

    Sep

ADOM

Adomani

$12.86

0.86 (7.17%)

, VLKAY

Volkswagen

$31.10

0.19 (0.61%)

13:06
08/17/17
08/17
13:06
08/17/17
13:06
Hot Stocks
Adomani sees $2.9B in settlement funds from Volkswagen »

Adomani (ADOM) announced…

ADOM

Adomani

$12.86

0.86 (7.17%)

VLKAY

Volkswagen

$31.10

0.19 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$11.89

-0.05 (-0.42%)

13:05
08/17/17
08/17
13:05
08/17/17
13:05
Options
Horizon Pharma call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLS

Celestica

$11.50

-0.08 (-0.69%)

13:04
08/17/17
08/17
13:04
08/17/17
13:04
Upgrade
Celestica rating change  »

Celestica upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDVX

Medovex

$0.95

0.05 (5.56%)

12:55
08/17/17
08/17
12:55
08/17/17
12:55
Hot Stocks
Medovex names Charlie Farrahar as CFO »

Medovex reported it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$33.20

-0.16 (-0.48%)

12:53
08/17/17
08/17
12:53
08/17/17
12:53
Hot Stocks
FDA posts approval of Pfizer's biologic license qpplication for Besponsa 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

  • 08

    Sep

  • 08

    Sep

  • 13

    Sep

NADL

North Atlantic Drilling

$1.44

-0.075 (-4.97%)

12:50
08/17/17
08/17
12:50
08/17/17
12:50
Options
Notable put spread in North Atlantic Drilling »

Notable put spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

12:45
08/17/17
08/17
12:45
08/17/17
12:45
General news
Breaking General news story  »

Dallas Federal Reserve…

HRB

H&R Block

$30.21

-0.53 (-1.72%)

12:40
08/17/17
08/17
12:40
08/17/17
12:40
Options
Higher option volume in H&R Block driven by call buying »

Higher option volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 14

    Sep

EXPE

Expedia

$148.78

1.72 (1.17%)

12:35
08/17/17
08/17
12:35
08/17/17
12:35
Options
Expedia put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:35
08/17/17
08/17
12:35
08/17/17
12:35
General news
Treasury Option Action: call buying at the long-end »

Treasury Option Action:…

ADP

ADP

$111.10

-0.48 (-0.43%)

12:32
08/17/17
08/17
12:32
08/17/17
12:32
Hot Stocks
Chapman says making dollar going against Ackman feels as good as $10 »

Robert Chapman of Chapman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 11

    Sep

ADP

ADP

$111.10

-0.48 (-0.43%)

12:31
08/17/17
08/17
12:31
08/17/17
12:31
Hot Stocks
Breaking Hot Stocks news story on ADP »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 11

    Sep

ADP

ADP

$111.10

-0.48 (-0.43%)

12:28
08/17/17
08/17
12:28
08/17/17
12:28
Hot Stocks
Breaking Hot Stocks news story on ADP »

Robert Chapman discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 11

    Sep

SPY

SPDR S&P 500 ETF Trust

$245.04

-1.9 (-0.77%)

, SPX

S&P 500

12:28
08/17/17
08/17
12:28
08/17/17
12:28
Technical Analysis
Technical View: S&P 500 hits lows of the day at midsession »

The S&P 500 (SPX) was…

SPY

SPDR S&P 500 ETF Trust

$245.04

-1.9 (-0.77%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Wal-Mart

$79.14

-1.84 (-2.27%)

, BABA

Alibaba

$166.91

7.4092 (4.65%)

12:25
08/17/17
08/17
12:25
08/17/17
12:25
General news
On The Fly: Top stock stories at midday »

Stocks opened in negative…

WMT

Wal-Mart

$79.14

-1.84 (-2.27%)

BABA

Alibaba

$166.91

7.4092 (4.65%)

AMZN

Amazon.com

$978.18

-4.56 (-0.46%)

AABA

Altaba

$60.65

0.66 (1.10%)

LB

L Brands

$35.15

-3.805 (-9.77%)

NTAP

NetApp

$42.41

0.44 (1.05%)

CSCO

Cisco

$32.34

0.25 (0.78%)

CTL

CenturyLink

$19.83

-1.06 (-5.07%)

LVLT

Level 3

$53.60

-1.58 (-2.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 17

    Aug

  • 17

    Aug

  • 18

    Aug

  • 23

    Aug

  • 24

    Aug

  • 06

    Sep

  • 06

    Sep

  • 14

    Sep

  • 16

    Nov

  • 20

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.